Business is booming
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Runner boo
Nice news
Yeah no maybe so
My gut parked this baby and being patient. No rush here. All the time in California! I mean the world
*Venmo
eBay must have been the backbone. Is there still a future? Everyone has already made a Amazon account with their credit cards already. Why switch to PP ?
You want me to bid for you too? Lol Texas, 3 established business already
This company is about to take over agriculture and horticulture. To the moon !
Wuz up
Cranking up
Ticky tocky
.094 is the new .07 … get your chart outta here lol
Thank you OK. Keeping the team spirit alive baby. Let’s goooo
And for those who forgot about this video
NBIO !! Bring on the stinking buyout ?!?
Heating up
Up up and away
Let’s gooooooo !
Nascent Biotech, Inc. is a biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer.
Our development strategy involves pursuing a novel target not being explored by other companies;
developing broad pipeline including therapies and diagnostics against the antigen, and platform drug delivery technology.
Our lead therapeutic asset, Pritumumab, has been validated in 249 human brain cancer patients.
Some of our achieved milestones include:
Re-engineered antibody into CHO cells; created and fully characterized
Master Cell Bank (MCB) in accord with FDA requirements
Developed scale-up CGMP-compliant manufacturing process; production of material for human clinical trials
Presented new clinical plan to FDA in pre-IND (Investigational New Drug) meeting
Successfully completed Toxicology studies
Secured NIH funding for novel “second generation” platform in collaboration with
MAPP Biopharma
Granted Orphan Drug Designation
Cleared IND 12/2018
Approved IRB 11/2019
Next stop, Curtis Jackson
Ok2kickass !! These hands are locked for the long run. Let’s go NBIO’ers
Let’s go
Can’t wait for that morning we gap up! Solid. NBIO $$$
Last days of cheapies
Statement of Ownership (sc 13g)
Source: Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Amendment No. )
Nascent Biotech Inc.
(Name of Issuer)
Common Shares
(Title of Class of Securities)
63108Q101
(CUSIP Number)
May 28, 2021
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
?
Rule 13d-1(b)
?
Rule 13d-1(c)
?
Rule 13d-1(d)
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13G
CUSIP NO. 63108 Q101
Page 2 of 5 Pages
1.
Name of Reporting Person I.R.S. Identification No. of above persons (entities only):
Sidney J. Lorio Jr. and Gloria Lorio, JTWROS
2.
Check the appropriate Box if a Member of a Group:
(a) ?
(b) ?
3.
SEC Use Only:
4.
Citizenship or Place of Organization:
United States
Number of
Shares
Beneficially Owned by
Each Reporting
Person With
5.
Sole Voting Power:
7,281,249
6.
Shared Voting Power:
0
7.
Sole Dispositive Power:
7,281,249
8.
Shared Dispositive Power:
0
9.
Aggregate Amount Beneficially Owned by Each Reporting Person:
7,281,249
10.
Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
?
11.
Percent of Class Represented by Amount in Row (9):
6.80%
12.
Type of Reporting Person:
Individual
SCHEDULE 13G
CUSIP NO. 63108 Q101
Page 3 of 5 Pages
Item 1. Name of Issuer
(a)
Name of Issuer: Nascent Biotech Inc.
(b)
Address of Issuer’s Principal Executive Offices: 6330 Nancy Ridge Drive Suite 105 San Diego, CA 92121
Item 2. Name of Person Filing
(a)
Name of Person Filing: Sidney J. Lorio Jr. and Gloria Lorio, JTWROS
(b)
Address of Principal Business Office or, if None, Residence: 2116 Parkwood Drive, Bedford, TX 76021
(c)
Citizenship: USA
(d)
Title of Class of Securities: Common shares
(e)
CUSIP Number: 63108 Q101
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
(a)
?
Broker or dealer registered under Section 15 of the Act;
(b)
?
Bank as defined in Section 3(a)(6) of the Act;
(c)
?
Insurance company as defined in Section 3(a)(19) of the Act;
(d)
?
Investment company registered under Section 8 of the Investment Company Act;
(e)
?
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)
?
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
(g)
?
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h)
?
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
(i)
?
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)
?
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
SCHEDULE 13G
CUSIP NO. 63108 Q101
Page 4 of 5 Pages
Item 4. Ownership.
(a)
Amount Beneficially Owned: 7,281,249
(b)
Percent of Class: 6.80%
(c)
Number of shares as to which such person has:
(i)
sole power to vote or to direct the vote: 7,281,249
(ii)
shared power to vote or to direct the vote:
(iii)
sole power to dispose or to direct the disposition of: 7,281,249
(iv)
shared power to dispose or to direct the disposition of:
Item 5. Ownership of Five Percent or Less of a Class.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
Item 8. Identification and Classification of Members of the Group.
Item 9. Notice of Dissolution of Group.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SCHEDULE 13G
CUSIP NO. 63108 Q101
Page 5 of 5 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Sidney J. Lorio Jr. and Gloria Lorio, JTWROS
/s/ Sidney J. Lorio Jr Gloria Lorio
Lmao
Titty twisters >
https://www.biospace.com/article/releases/nascent-biotech-earns-us-patent-for-crossing-blood-brain-barrier/
Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce that the Company has officially received allowance for a "Method-of-Use" patent by the US Patent and Trademark Office ("USPTO") for their primary asset, Pritumumab ("PTB"). Specifically, the patent approval is related to PTB's ability to cross the Blood-Brain Barrier ("BBB").
The recent patent allowance recognizes PTB's ability to act as a monotherapy, as well as its potential to act as a conjugate, bringing other therapies across the BBB.
The blood-brain barrier is a semipermeable border of endothelial cells that act as a filtering mechanism for the capillaries that carry blood to the brain and spinal cord tissue, blocking the passage of certain substances from the circulatory system into the brain.
Nascent's senior management recognizes this patent approval as a landmark event for the Company's value proposition. The approval strengthens the Company's intellectual property position significantly by providing protection that extends well beyond the Company's Orphan Drug Designation.
"PTB has demonstrated value on a number of different levels, and its capacity to cross the blood-brain barrier is a key facet of that equation," remarked Nascent CEO, Sean Carrick. "On the heels of our success in collaboration with Syracuse University with regard to PTB's value in blocking viral cell entry, this new method-of-use patent is another major step that represents a significant expansion in potential market impact. We look forward to updating shareholders with additional details over the near term."
Slow and deep baby! …Wait that’s not right hahaa NBIO $$$
ITEM 8.01 OTHER EVENTS
On June 8, 2021, the United States Patent Office issued US Patent 11,028,155 to the Company. The patent is for Enhanced Delivery of Drugs to the Brain. This was the official issuance of the Patent.
The Phase 1 clinical trial has commenced enrollment of patients for the second cohort. People interested in more details concerning the trial may visit: https://www.clinicaltrials.gov/ct2/results?term=pritumumab&type=Intr&cond=Brain+Cancer&phase=0
Maybe it’s all your bad singing
.10 by Friday ?!
Let’s go Hawk!
My spider senses tingling, more news this week ?